Tuesday, February 13, 2018

Company discusses strategy on eve of first recreational cannabis sales

MassRoots,
Inc. ("MassRoots" or the "Company") (OTCQB:MSRT), one of the leading
technology platforms for the regulated cannabis industry, today
announced a comprehensive action plan to aggressively scale its market
share of cannabis consumers and businesses in the California market. On January 3, 2018, the first recreational cannabis sales are expected to begin in California, which ArcView Market Research projects will grow to $6.5 billion by 2020.

Powered by more than one million registered
users, MassRoots enables consumers to rate products and strains based on
their efficacy (i.e., effectiveness for treating ailments such as
back-pain or epilepsy) and then presents this information in easy-to-use
formats for consumers to make educated purchasing decisions at their
local dispensary. Businesses are able to leverage MassRoots by
strategically advertising to consumers based on their preferences and
tendencies.

MassRoots has launched a comprehensive social
media campaign leveraging its 450,000 followers on Instagram, 500,000
followers on Facebook, and more than 100,000 followers on Snapchat, in
addition to its network of more than 75 cannabis-centric social media
influencers with combined followings of more than 5,000,000 people. The
campaign is focused on driving and rewarding referrals of users and
paying businesses to the MassRoots platform.

"We believe California offers the opportunity of a lifetime for MassRoots and its shareholders," stated MassRoots Chief Executive Officer Mr. Isaac Dietrich.
"There are thousands of businesses are in the process of revamping
their operations to be in compliance with newly-implemented state
regulations. Our goal is to have as many of these business processes
utilizing the MassRoots platform as possible and establish our Company
as a dominant player in the California cannabis market."

About MassRootsMassRoots, Inc. is
one of the leading technology platforms for the regulated cannabis
industry. Powered by more than one million registered users, the
Company's mobile apps empower consumers to make educated cannabis
purchasing decisions through community-driven reviews. Its compliance
and point-of-sale system, MassRoots Retail, enables cannabis-related
businesses to streamline their retail operations and manage compliance
reporting to state regulators. With a significant market share of
medical cannabis patients in certain markets and more than 25,000
shareholders, the Company believes it is uniquely positioned to best
serve the needs of the cannabis industry. For more information, please
visit MassRoots.com/Investors and review MassRoots' filings with the U.S. Securities and Exchange Commission.

Company continues to strengthen its balance sheet as it expands into blockchain technology for the cannabis industry

MassRoots,
Inc. ("MassRoots" or the "Company") (OTCQB:MSRT), one of the leading
technology platforms for the regulated cannabis industry, today
announced all notes issued pursuant to the Company's August 2017
debt offering have been retired and the Company has no further
obligations under the notes of that offering. More information is
available on the Company's Current Report on Form 8-K filed on January 17, 2018.

"We're excited to have this convertible debt
fully retired as we continue to strengthen MassRoots' balance sheet and
drive shareholder value," stated MassRoots Chief Executive Officer Mr. Isaac Dietrich.
"With California's recreational cannabis market recently coming online
and our expansion into blockchain technology, we believe MassRoots is
well positioned to deliver growth in 2018."
Powered by more than one million registered
users, MassRoots enables consumers to rate products and strains based on
their efficacy (i.e., effectiveness for treating ailments such
back-pain or epilepsy) and then presents this information in easy-to-use
formats for consumers to make educated purchasing decisions at their
local dispensary. Businesses are able to leverage MassRoots by
strategically advertising to consumers based on their preferences and
tendencies. More information on MassRoots' blockchain expansion is
available at www.MassRootsBlockchain.com.

About MassRoots
MassRoots, Inc. is one of the leading
technology platforms for the regulated cannabis industry. Powered by
more than one million registered users, the Company's mobile apps
empower consumers to make educated cannabis purchasing decisions through
community-driven reviews. Its compliance and point-of-sale system,
MassRoots Retail, enables cannabis-related businesses to streamline
their retail operations and manage compliance reporting to state
regulators. With a significant market share of medical cannabis patients
in certain markets and more than 25,000 shareholders, the Company
believes it is uniquely positioned to best serve the needs of the
cannabis industry. For more information, please visit MassRoots.com/Investors and review MassRoots's filings with the U.S. Securities and Exchange Commission.

MassRoots, Inc. ("MassRoots" or the "Company") (OTCQB:MSRT), one of the
leading technology platforms for the regulated cannabis industry, today
announced it has formed MassRoots Blockchain Technologies, Inc., a
wholly-owned subsidiary of MassRoots, Inc. dedicated to developing
blockchain-based solutions for the cannabis industry. More information
is available at www.MassRootsBlockchain.com.

"We believe blockchain has the potential to enable the cannabis
industry to operate more efficiently and with a greater degree of
accountability and transparency," stated MassRoots Chief Executive
Officer Isaac Dietrich.
"MassRoots looks forward to being a pioneer in exploring
blockchain-based solutions for the multi-billion dollar cannabis
industry."

"The blockchain is an incorruptible digital
ledger of economic transactions that can be programmed to record not
just financial transactions but virtually everything of value,"
according to Dan and Alex Tapscott
in the Blockchain Revolution (2016). The most well-known application to
blockchain technology has been cryptocurrencies, which have grown to a
market valued at more than $600 billion,
according to CoinMarketCap.com. The broadening of this technology spans
many other applications and creates various opportunities within the
regulated cannabis market.

Seed-to-Sale TrackingDistributed
ledger technology provides a greater degree of reliability and accuracy
on the metadata associated with products -- times, dates, locations,
quantities -- which have the potential to reduce friction in the
cannabis market-place, save businesses valuable resources, and provide
greater transparency to government regulators. According to Bloomberg,
IBM is also exploring how blockchain can improve seed-to-sale
traceability in the cannabis market. MassRoots Blockchain is exploring
how this new technology can improve its point-of-sale system, MassRoots
Retail, formerly known as Odava.

Smart ContractsBlockchain enables
the development of contracts that automatically execute when certain
parameters are met -- for example, a dispensary can automatically order
more supply of a particular strain when its inventories reach a certain
threshold. The smart contract has the potential to add substantial
efficiency to the supply chain and resource planning processes within
the cannabis industry. MassRoots Blockchain is exploring how to
integrate this technology with its platform.

Eliminating Intermediaries
In the
sharing economy as it exists today, buyers and sellers have to go
through intermediaries to conduct a transaction (such as AirBnB for
short-term rentals and Uber for ride-sharing). The blockchain enables
peer-to-peer transactions without third parties, meaning that personal
and business reputation can be verified and thus more reliable.
MassRoots Blockchain is exploring how this can be applied to producers
of cannabis and the dispensaries that purchase from them.

Corporate GovernanceBlockchain has the potential to make
the validation and results of elections fully-transparent and
immediately accessible online. MassRoots Blockchain is exploring how
distributed-ledger technology can be applied to proxy voting and giving
MassRoots' shareholders a greater degree of transparency and
communication.

Identity ManagementSocial networks
such as MassRoots collect a significant amount of metadata on its
users. Blockchain has the potential to streamline its collection and
organization, while eliminating traditional security risks. This would
enable advertisers to better target consumers, reduce the risk of
security breaches, and enable the development of solutions that better
serve the MassRoots community.

About MassRootsMassRoots, Inc. is
one of the leading technology platforms for the regulated cannabis
industry. Powered by more than one million registered users, the
Company's mobile apps empower consumers to make educated cannabis
purchasing decisions through community-driven reviews. Its compliance
and point-of-sale system, MassRoots Retail, enables cannabis-related
businesses to streamline their retail operations and manage compliance
reporting to state regulators. With a significant market share of
medical cannabis patients in certain markets and more than 25,000
shareholders, the Company believes it is uniquely positioned to best
serve the needs of the cannabis industry. For more information, please
visit MassRoots.com/Investors and review MassRoots' filings with the U.S. Securities and Exchange Commission.

Wednesday, February 7, 2018

-
To be a shareholder of record, investors are advised to own Actinium
stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2
settlement timing

- Actinium’s executive management and directors have indicated their intent to subscribe to the rights offering

Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"),
today issued a reminder to shareholders that the Record Date of its
proposed rights offering is February 14, 2018. To be a shareholder of
record, ownership of Actinium stock must occur by market close of
February 12, 2018 to account for settlement.

Under
the proposed rights offering, Actinium would distribute
non-transferable subscription rights to purchase 35,714,285 units at a
subscription price per unit of $0.70, to its stockholders and certain
participating warrant holders on the record date. The subscription
rights will be exercisable for up to an aggregate of $25.0 million of
units, subject to increase at the discretion of the Company, with
aggregate participation to be allocated among holders on a pro rata
basis if in excess of that threshold.

Each unit
will consist of one share of common stock, 0.25 series A warrants and
0.75 series B warrants. The series A warrants will have a term of 12
months from the date of issuance and will be exercisable at a price of
$0.90. The series B warrants will have a term of 30 months from the
date of issuance and will have an exercise price of $1.10. Holders who
fully exercise their basic subscription rights will be entitled, if
available, to subscribe for an additional amount of units that are not
purchased by other holders, on a pro rata basis and subject to the $25.0
million aggregate offering threshold and other ownership limitations.
The subscription rights are non-transferrable and may only be exercised
during the anticipated subscription period of Thursday, February 15,
2018 through 5:00 PM ET on Friday, March 2, 2018, unless extended.

Actinium’s
executive management and directors have indicated their intent to
subscribe to the rights offering. Investors are advised to ensure they
own Actinium’s stock as of 4:00 PM ET on Monday, February 12, 2018 to be
considered a stockholder of record on Wednesday, February 14, 2018, to
take into account T+2 settlement timing.

The expected calendar for the rights offering is as follows:

Monday,
February 12, 2018: Buy-In Deadline - to be considered a stockholder of
record on Wednesday, February 14, 2018, shares should be acquired by
this date.

Actinium
intends to use the proceeds from the rights offering to complete its
ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate
Iomab-B, generate topline results and support the filing of a BLA
application with the U.S. Food and Drug Administration (FDA) all of
which are anticipated to be approximately $12 to 15 million. Iomab-B is
a first in class therapy being developed for myeloablation and
conditioning of the bone marrow prior to a bone marrow transplant for
patients with relapsed or refractory acute myeloid leukemia (AML) age 55
and older. The SIERRA trial is randomized and controlled 150-patient
trial that is currently active at 15 clinical trial sites in the United
States. Actinium’s CD33 program is currently comprised of an ongoing
Phase 2 clinical trial for Actimab-A and Phase 1 trial for Actimab-M
which are expected to generate top line results in 2018 as well as a
planned Phase 2 trial for Actimab-MDS. The Company intends to partner
the CD33 program and believes that data from these trials as well as the
Actimab-MDS trial will support this strategy and establish its program
as the industry leader. Consequently, the Company may elect to use any
additional proceeds above $15 million to fund proof-of-concept of its
planned Phase 2 Actimab-MDS trial from the CD33 Program, if appropriate,
as it believes this can further support its partnering strategy for the
CD33 program. Actinium will also use the proceeds to support its AWE
Technology Platform, research and development and general working
capital needs.

Actinium has engaged Maxim Group
LLC as dealer-manager for the Rights Offering. Questions about the
rights offering or requests for a prospectus may be directed to
Broadridge Corporate Issuer Solutions, Inc., Actinium’s information
agent for the rights offering, by calling (855) 793-5068 (toll-free); or
to Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention
Syndicate Department, email: syndicate@maximgrp.com or telephone (212)
895-3745.

This press release does not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor will there be any sale of these securities in any state
or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.

A
registration statement on Form S-3 relating to these securities has been
filed by the Company with the SEC. The rights offering will only be
made by means of a prospectus. A preliminary prospectus relating to and
describing the proposed terms of the rights offering has been filed
with the SEC as a part of the registration statement and is available on
the SEC’s web site.

About Actinium Pharmaceuticals, Inc.

Actinium
Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company
focused on developing and commercializing targeted therapies for
potentially superior myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant and for the targeting and killing of
cancer cells. Our targeted therapies have demonstrated the potential to
result in significantly improved access to bone marrow transplant with
better outcomes, namely increased marrow engraftment and survival. Our
targeted therapies are ARC’s or Antibody Radio-Conjugates that combine
the targeting ability of monoclonal antibodies with the cell killing
ability of radioisotopes. Three of our four ARC drug candidates are
based on our AWE or Actinium Warhead Enabling Technology Platform that
utilizes the isotope Actinium-225 (Ac225) that emits alpha
particles. We are currently conducting clinical trials for our four
product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as
well as performing research on other potential drug candidates utilizing
our proprietary AWE Technology Platform. Our most advanced product
candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer
Research Center, is comprised of an anti-CD45 monoclonal antibody
labeled with iodine-131. We are currently conducting a pivotal Phase 3
trial of Iomab-B for myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant for patients with relapsed or
refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow
transplant is a potentially curative treatment for patients with AML
and other blood cancers including leukemias, lymphomas and multiple
myeloma as well as certain blood disorders. Iomab-B has been tested in
several of these other cancers with over five hundred patients treated
in several Phase 1 and 2 trials with promising results. Upon successful
completion of our Phase 3 clinical trial for Iomab-B we intend to
submit this candidate for marketing approval in the U.S. and European
Union where it has been designated as an Orphan Drug. We are also
developing a potentially best in class CD33 program using an ARC
comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with
the alpha-particle emitter actinium-225. Our most advanced CD33 program
candidate, Actimab-A, is currently in a Phase 2 clinical trial for
patients advanced over the age of 60 who are newly diagnosed with AML
and ineligible for standard induction chemotherapy. Actimab-A also has
Orphan Drug designation in the US and EU. Actimab-M, our second CD33
targeting ARC, is being studied in a Phase 1 trial for patients with
refractory multiple myeloma. Actinium is also planning a Phase 2 trial
for Actimab-MDS, our third CD33 program candidate, as a conditioning
regimen prior to a bone marrow transplant for patients with MDS that
have a p53 genetic mutation. Our AWE or Actinium Warhead Enabling
Technology Platform, originally developed in conjunction with Memorial
Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know
how and intellectual property to create additional ARC drug candidates
by labeling Ac225 to targeting moieties that we will either progress in clinical trials ourselves or out-license.

- Conference call to be held on Tuesday, February 13, 2018 at 4:30 PM ET

Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"),
announced today that the Company is initiating a new clinical trial
that will study Actimab-A in combination with CLAG-M for patients with
relapsed or refractory acute myeloid leukemia (AML). CLAG-M is a
salvage chemotherapy regimen that consists of cladribine, cytarabine,
and filgrastim with mitoxantrone for patients with relapsed or
refractory AML. The combination trial will be a Phase 1,
dose-escalation study that will be conducted at the Medical College of
Wisconsin by principal investigator Dr. Ehab Atallah.

Dr.
Mark Berger, Actinium’s Chief Medical Officer said, “Relapsed and
refractory AML patients unfortunately have limited treatment options
that have little clinical benefit for patients. Actimab-A is ideally
suited to be studied in combination with other therapeutic modalities
like CLAG-M given its potency and minimal extramedullary toxicities. We
are optimistic that this novel combination will demonstrate Actimab-A’ s
key strengths through higher response rates, a greater number of
patients successfully receiving a bone marrow transplant and ultimately,
survival. Further, it will demonstrate the value of using Actimab-A in
combinations as we believe that combination therapies will be the next
wave in the treatment of patients with AML just as combinations of
regimen’s approved in multiple myeloma over the past three or four years
have become for patients with that disease.”

Actinium
will host a conference call on Tuesday, February 13, 2018 at 4:30 PM ET
that will be led by Dr. Mark Berger, Actinium’s Chief Medical Officer
and Dr. Atallah.

Sandesh
Seth, Actinium’s Chairman and CEO said, “This latest clinical
initiative is especially exciting as it further demonstrates that we are
building the industry leading CD33 Program. We the only company with
multi-disease, multi-indication clinical trials with our ongoing
Actimab-A, Actimab-M and planned Actimab-MDS studies and this latest
initiative has the potential of extending the addressable patient
population for Actimab-A. This is a viable approach for Actimab-A as we
begin to strategize and implement the next phase of Actimab-A’s
development. In doing so, we expect to maximize the value of our CD33
program and increase its synergies for potential partners and
collaborators. Further, this initiative is aligned with Actinium’s core
strategy of improving access and outcomes to transplants and one we are
excited to embark on.”

Actimab-A is Actinium’s
lead drug candidate from its CD33 program and is an Antibody
Radio-Conjugate (ARC) that is comprised of the CD33 targeting antibody
lintuzumab and actinium-225, an alpha-emitting radioisotope. Actimab-A
is currently being studied in Phase 2 clinical trial in patients that
are newly diagnosed with AML who are over the age of 60 that are
ineligible for intense chemotherapy, also known as unfit patients. The
Company expects to complete patient enrollment of the Phase 2 trial in
the first half of 2018 and report top line data results in the second
half of 2018. The Company is also developing Actimab-M and Actimab-MDS,
which are also CD33 actinium-225 ARCs. Actimab-M is being studied in a
Phase 1 investigator-initiated trial for patients with refractory
multiple myeloma. The Phase 1 Actimab-M trial is expected to complete
enrollment and report top like data in the second half of 2018.
Actimab-MDS is expected to begin a Phase 2 clinical trial in the second
half of 2018 following a pre-IND meeting with the FDA in the first half
of 2018. Actimab-MDS is intended to bridge patients with high-risk
myelodysplastic syndrome (MDS) that have a p53 genetic mutation to a
bone marrow transplant via targeted myeloablation.

About Actinium Pharmaceuticals, Inc.

Actinium
Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company
focused on developing and commercializing targeted therapies for
potentially superior myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant and for the targeting and killing of
cancer cells. Our targeted therapies have demonstrated the potential to
result in significantly improved access to bone marrow transplant with
better outcomes, namely increased marrow engraftment and survival. Our
targeted therapies are ARC’s or Antibody Radio-Conjugates that combine
the targeting ability of monoclonal antibodies with the cell killing
ability of radioisotopes. Three of our four ARC drug candidates are
based on our AWE or Actinium Warhead Enabling Technology Platform that
utilizes the isotope Actinium-225 (Ac225) that emits alpha
particles. We are currently conducting clinical trials for our four
product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as
well as performing research on other potential drug candidates utilizing
our proprietary AWE Technology Platform. Our most advanced product
candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer
Research Center, is comprised of an anti-CD45 monoclonal antibody
labeled with iodine-131. We are currently conducting a pivotal Phase 3
trial of Iomab-B for myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant for patients with relapsed or
refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow
transplant is a potentially curative treatment for patients with AML
and other blood cancers including leukemias, lymphomas and multiple
myeloma as well as certain blood disorders. Iomab-B has been tested in
several of these other cancers with over five hundred patients treated
in several Phase 1 and 2 trials with promising results. Upon successful
completion of our Phase 3 clinical trial for Iomab-B we intend to
submit this candidate for marketing approval in the U.S. and European
Union where it has been designated as an Orphan Drug. We are also
developing a potentially best in class CD33 program using an ARC
comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with
the alpha-particle emitter actinium-225. Our most advanced CD33 program
candidate, Actimab-A, is currently in a Phase 2 clinical trial for
patients advanced over the age of 60 who are newly diagnosed with AML
and ineligible for standard induction chemotherapy. Actimab-A also has
Orphan Drug designation in the US and EU. Actimab-M, our second CD33
targeting ARC, is being studied in a Phase 1 trial for patients with
refractory multiple myeloma. Actinium is also planning a Phase 2 trial
for Actimab-MDS, our third CD33 program candidate, as a conditioning
regimen prior to a bone marrow transplant for patients with MDS that
have a p53 genetic mutation. Our AWE or Actinium Warhead Enabling
Technology Platform, originally developed in conjunction with Memorial
Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know
how and intellectual property to create additional ARC drug candidates
by labeling Ac225 to targeting moieties that we will either progress in clinical trials ourselves or out-license.

Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company")
announced today that it has filed a preliminary prospectus supplement
as a part of a registration statement on Form S-3 with the Securities
and Exchange Commission (SEC) for a rights offering to stockholders and
certain participating warrant holders of record on Wednesday, February
14, 2018.

Under the proposed rights
offering, Actinium would distribute non-transferable subscription rights
to purchase 35,714,285 units at a subscription price per unit of $0.70,
to its stockholders and certain participating warrant holders on the
record date. The subscription rights will be exercisable for up to an
aggregate of $25.0 million of units, subject to increase at the
discretion of the Company, with aggregate participation to be allocated
among holders on a pro rata basis if in excess of that threshold.

Each
unit will consist of one share of common stock, 0.25 series A warrants
and 0.75 series B warrants. The series A warrants will have a term of
12 months from the date of issuance and will be exercisable at a price
of $0.90. The series B warrants will have a term of 30 months from the
date of issuance and will have an exercise price of $1.10. Holders who
fully exercise their basic subscription rights will be entitled, if
available, to subscribe for an additional amount of units that are not
purchased by other holders, on a pro rata basis and subject to the $25.0
million aggregate offering threshold and other ownership limitations.
The subscription rights are non-transferrable and may only be exercised
during the anticipated subscription period of Thursday, February 15,
2018 through 5:00 PM ET on Friday, March 2, 2018, unless extended.

Investors
are advised to ensure they own Actinium’s stock as of 4:00 PM ET on
Monday, February 12, 2018 to be considered a stockholder of record on
Wednesday, February 14, 2018, to take into account T+2 settlement
timing.

The expected calendar for the rights offering is as follows:

Monday,
February 12, 2018: Buy-In Deadline - to be considered a stockholder of
record on Wednesday, February 14, 2018, shares should be acquired by
this date.

Actinium
intends to use the proceeds from the rights offering to complete its
ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate
Iomab-B, generate topline results and support the filing of a BLA
application with the U.S. Food and Drug Administration (FDA) all of
which are anticipated to be approximately $12 to $15 million. Iomab-B
is a first in class therapy being developed for myeloablation and
conditioning of the bone marrow prior to a bone marrow transplant for
patients with relapsed or refractory acute myeloid leukemia (AML) age 55
and older. The SIERRA trial is randomized and controlled 150-patient
trial that is currently active at 15 clinical trial sites in the United
States. Actinium’s CD33 program is currently comprised of an ongoing
Phase 2 clinical trial for Actimab-A and Phase 1 trial for Actimab-M
which are expected to generate top line results in 2018 as well as a
planned Phase 2 trial for Actimab-MDS. The Company intends to partner
the CD33 program and believes that data from these trials as well as the
Actimab-MDS trial will support this strategy and establish its program
as the industry leader. Consequently, the Company may elect to use any
additional proceeds above $15 million to fund proof-of-concept of its
planned Phase 2 Actimab-MDS trial from the CD33 Program, if appropriate,
as it believes this can further support its partnering strategy for the
CD33 program. Actinium will also use the proceeds to support its AWE
Technology Platform, research and development and general working
capital needs.

Actinium has engaged Maxim Group
LLC as dealer-manager for the Rights Offering. Questions about the
rights offering or requests for a prospectus may be directed to
Broadridge Corporate Issuer Solutions, Inc., Actinium’s information
agent for the rights offering, by calling (855) 793-5068 (toll-free); or
to Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention
Syndicate Department, email: syndicate@maximgrp.com or telephone (212)
895-3745.

This press release does not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor will there be any sale of these securities in any state
or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.

A
registration statement on Form S-3 relating to these securities has been
filed by the Company with the SEC. The rights offering will only be
made by means of a prospectus. A preliminary prospectus relating to and
describing the proposed terms of the rights offering has been filed
with the SEC as a part of the registration statement and is available on
the SEC’s web site.

About Actinium Pharmaceuticals, Inc.

Actinium
Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company
focused on developing and commercializing targeted therapies for
potentially superior myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant and for the targeting and killing of
cancer cells. Our targeted therapies have demonstrated the potential to
result in significantly improved access to bone marrow transplant with
better outcomes, namely increased marrow engraftment and survival. Our
targeted therapies are ARC’s or Antibody Radio-Conjugates that combine
the targeting ability of monoclonal antibodies with the cell killing
ability of radioisotopes. Three of our four ARC drug candidates are
based on our AWE or Actinium Warhead Enabling Technology Platform that
utilizes the isotope Actinium-225 (Ac-225) which emits alpha particles.
We are currently conducting clinical trials for our four product
candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as
performing research on other potential drug candidates utilizing our
proprietary AWE Technology Platform. Our most advanced product
candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer
Research Center, is comprised of an anti-CD45 monoclonal antibody
labeled with iodine-131. We are currently conducting a pivotal Phase 3
trial of Iomab-B for myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant for patients with relapsed or
refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow
transplant is a potentially curative treatment for patients with AML
and other blood cancers including leukemias, lymphomas and multiple
myeloma as well as certain blood disorders. Iomab-B has been tested in
several of these other cancers with over five hundred patients treated
in several Phase 1 and 2 trials with promising results. Upon successful
completion of our Phase 3 clinical trial for Iomab-B we intend to
submit this candidate for marketing approval in the U.S. and European
Union where it has been designated as an Orphan Drug. We are also
developing a potentially best in class CD33 program using an ARC
comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with
the alpha-particle emitter Ac-225. Our most CD33 program candidate,
Actimab-A, is currently in a Phase 2 clinical trial for patients
advanced over the age of 60 who are newly diagnosed with AML and
ineligible for standard induction chemotherapy. Actimab-A also has
Orphan Drug designation in the US and EU. Actimab-M, our second CD33
targeting ARC, is being studied in a Phase 1 trial for patients with
refractory multiple myeloma. Actinium is also planning a Phase 2 trial
for Actimab-MDS, our third CD33 program candidate, as a conditioning
regimen prior to a bone marrow transplant for patients with MDS that
have a p53 genetic mutation. Our AWE or Actinium Warhead Enabling
Technology Platform, originally developed in conjunction with Memorial
Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know
how and intellectual property to create additional ARC drug candidates
by labeling Ac-225 to targeting moieties that we will either progress in
clinical trials ourselves or out-license.

Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company")
announced today that its abstract has been accepted for a poster
presentation at the 2018 American Association for Cancer Research (AACR)
Annual Meeting being held April 14-18, 2018 in Chicago, Illinois. The
abstract showcases the potential of Actinium’s AWE Technology Platform,
specifically, the ability of actinium-225 to enhance the in vivo
efficacy of daratumumab, a CD38 targeting therapy that is marketed by
Johnson & Johnson as Darzalex®.

Per
the abstract submission highlighted below, the Ac-225 labelled
daratumumab at an equimolar concentration demonstrated superior
antitumor activity to naked daratumumab in a highly predictive DAUDI
model and provided a survival benefit. Additional details will be
available at the time of the Annual Meeting. The Company had earlier
presented initial in vitro data at ASH which studied the effect of
Actinium-225 labeled daratumumab on DAUDI, 28BM and 28PE cell lines at
the 48, 72 and 96 hour time points as well as U226, a cell line that
does not express CD38. The results showed that when daratumumab is
labeled with Actinium-225, cell death was increased as much as ten-fold,
approaching one-hundred percent cell death in certain cell lines and at
certain time points, and in all three cell lines tested the
Actinium-225 labeled daratumumab had higher cell death compared to naked
daratumumab. In addition, immunogenicity was preserved with most or
all of daratumumab’s CD38 targeting ability maintained, high rates of
radioisotope labeling of the antibody from 82-85% was demonstrated, as
was high rates of stability from 73-87% at various temperatures
forty-eight hours post labeling.

Sandesh
Seth, Actinium’s Chairman and Chief Executive Officer said, “We are
excited to build upon the already exciting data from our AWE Program and
are looking forward to presenting new data from our continued efforts.
The data we will present will exemplify Actinium’s expanding R&D
capabilities and the potential of our AWE technology platform, which are
now being spearheaded by our new Chief Scientific Officer, Dr. Dale
Ludwig. This is the first AACR that Actinium has presented data at and
we look forward to a growing and impactful presence as we are committed
to continuing to leverage our AWE technology and extending our
capabilities both on behalf of our internal efforts but also for
partners”

About Our Actinium Warhead Enabling Technology Platform

The
Actinium Warhead Enabling (AWE) Technology Platform enables a highly
potent and selective form of targeted therapy that combines the powerful
alpha-emitting radioisotope actinium-225 with targeting agents, which
are designed to seek out cancer cells in the body that express
particular markers. Actinium-225 emits significant alpha radiation
making it a potent treatment modality against targeted cancer cells
while limiting damage to healthy tissues as its radiation travels
extremely short distances in the body. When labeled to targeting agents,
actinium-225 can be delivered directly to cancer cells where the high
linear energy transfer resulting from the emission of alpha particles
results in irreparable DNA double stranded breaks and ultimately cancer
cell death. Despite this superior cell killing power, actinium-225 when
delivered in a targeted manner is sparing of the surrounding
environment in the body due to the short path length of its
alpha-particle radiation and can result in a superior safety profile.
Actinium Pharmaceuticals owns or has licensed the rights to several
issued and pending patents that pertain to its AWE Technology Platform
including technology to manufacture Actinium-225 in a cyclotron. In
addition, the Company obtains actinium-225 from various sources such as
the U.S. Department of Energy at Oak Ridge National Laboratories and has
developed considerable know-how, expertise and validated processes
related to production of Actinium Radio-Conjugates (ARC’s), management
of the supply chain and dealing with various regulatory bodies. The AWE
Technology Platform can be utilized to potentially improve the
cell-killing power of targeting agents such as antibodies, peptides, Fab
fragments, nanobodies etc. via labeling with Actinium-225. In addition
to increased efficacy, these Actinium-225 enhanced targeting agents can
offer optimized dosing or administration and in the case of approved
targeting agents provide an opportunity to extend intellectual property
protection by the creation of biobetters or improved versions of the
approved agent. The Company’s Actinium Warhead Enabling (AWE) Program
can be accessed by biopharmaceutical companies that are interested in
creating biobetters through the utilization of the AWE Platform
Technology. To learn more about the AWE Technology Platform or the AWE
Program please contact Keisha Thomas, Ph.D., Corporate Development at
kthomas@actiniumpharma.com.

About Actinium Pharmaceuticals, Inc.

Actinium
Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company
focused on developing and commercializing targeted therapies for
potentially superior myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant and for the targeting and killing of
cancer cells. Our targeted therapies have demonstrated the potential to
result in significantly improved access to bone marrow transplant with
better outcomes, namely increased marrow engraftment and survival. Our
targeted therapies are ARC’s or Actinium Radio-Conjugates that combine
the targeting ability of monoclonal antibodies with the cell killing
ability of radioisotopes. Three of our four ARC drug candidates are
based on our AWE or Actinium Warhead Enabling Technology Platform that
utilizes the isotope Actinium-225 (Ac-225) which emits alpha particles.
We are currently conducting clinical trials for our four product
candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as
performing research on other potential drug candidates utilizing our
proprietary AWE Technology Platform. Our most advanced product
candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer
Research Center, is comprised of an anti-CD45 monoclonal antibody
labeled with iodine-131. We are currently conducting a pivotal Phase 3
trial of Iomab-B for myeloablation and conditioning of the bone marrow
prior to a bone marrow transplant for patients with relapsed or
refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow
transplant is a potentially curative treatment for patients with AML and
other blood cancers including leukemias, lymphomas and multiple myeloma
as well as certain blood disorders. Iomab-B has been tested in several
of these other cancers with over five hundred patients treated in
several Phase 1 and 2 trials with promising results. Upon successful
completion of our Phase 3 clinical trial for Iomab-B we intend to submit
this candidate for marketing approval in the U.S. and European Union
where it has been designated as an Orphan Drug. We are also developing a
potentially best in class CD33 program using an ARC comprised of the
anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle
emitter Ac-225. Our most CD33 program candidate, Actimab-A, is
currently in a Phase 2 clinical trial for patients advanced over the age
of 60 who are newly diagnosed with AML and ineligible for standard
induction chemotherapy. Actimab-A also has Orphan Drug designation in
the US and EU. Actimab-M, our second CD33 targeting ARC, is being
studied in a Phase 1 trial for patients with refractory multiple
myeloma. Actinium is also planning a Phase 2 trial for Actimab-MDS, our
third CD33 program candidate, as a conditioning regimen prior to a bone
marrow transplant for patients with MDS that have a p53 genetic
mutation. Our AWE or Actinium Warhead Enabling Technology Platform,
originally developed in conjunction with Memorial Sloan Kettering Cancer
Center, is focused on leveraging Actinium’s know how and intellectual
property to create additional ARC drug candidates by labeling Ac-225 to
targeting moieties that we will either progress in clinical trials
ourselves or out-license.